During the past decade, Gwinnett Research Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 10 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gwinnett Research Institute" #1 sponsor was "Allergan" with 4 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "AMAG Pharmaceuticals, Inc." with 1 trials sponsored, "Applied Molecular Transport" with 1 trials sponsored and "Astellas Pharma Global Development, Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gwinnett Research Institute" #1 collaborator was "AbCellera Biologics Inc." with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "HealthCore-NERI" with 1 trials as a collaborator, "Molecular Partners AG" with 1 trials as a collaborator and "Shanghai Junshi Bioscience Co., Ltd." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Gwinnett Research Institute" are "Gastroparesis" (4 trials), "Diabetes Mellitus" (3 trials), "COVID-19" (2 trials), "Alzheimer Disease" (1 trials) and "Covid19" (1 trials). Many other conditions were trialed in "Gwinnett Research Institute" in a lesser frequency.

Most popular intervention types in "Gwinnett Research Institute" are "Drug" (14 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Relamorelin" (3 trials), "AMT-101 (oral)" (1 trials), "Bamlanivimab" (1 trials) and "Bebtelovimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Gwinnett Research Institute" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Gwinnett Research Institute". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Gwinnett Research Institute, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Gwinnett Research Institute, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".